For adults with type 2 diabetes and chronic kidney disease, taking semaglutide along with mineralocorticoid receptor antagonists does not lead to a meaningful increase in the risk of high blood...
Mechanism
Synthesis from 1 study
Semaglutide helps the kidneys flush out salt and water, which also helps remove potassium. The other drug slows down potassium removal, but it works in a different part of the kidney. Because they don’t interfere with each other, potassium levels don’t rise dangerously when both are used together.
Most probable mechanism
Semaglutide doesn’t interfere with how the kidneys get rid of potassium, even when another drug is slowing down potassium removal. So potassium levels stay stable.
Semaglutide enhances natriuresis and modestly increases glomerular filtration rate without altering distal tubular potassium secretion.
Mineralocorticoid receptor antagonists reduce sodium reabsorption and potassium excretion in the distal nephron by blocking aldosterone signaling.
The renal handling of potassium by semaglutide and mineralocorticoid receptor antagonists occurs through non-overlapping pathways, preventing additive effects on serum potassium.
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.